EU Pharma Package hits the final stretch—but can negotiators agree?

With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

WIPR debuts Global In-House Elite 2026

26 March 2026 LSIPR sister title launches vetted list celebrating leading in-house counsel who demonstrate exceptional ability in managing their organisation's IP portfolio, legal team, and IP culture.

Europe

UK court deals blow to Spanish pharma’s SPC bid for contraceptive

24 March 2026 The drugmaker’s attempt to extend protection for a fast-growing oestrogen-free contraceptive ran into a landmark EU ruling, with the court not persuaded to read it narrowly.

Europe

EPO reports record patent filings, but pharma and biotech lag

24 March 2026 The European Patent Office’s Technology Dashboard reveals only a slight increase in medtech filings, and drops in biotech and pharma, against an overall healthy backdrop.

More features

WIPR debuts Global In-House Elite 2026

UK court deals blow to Spanish pharma’s SPC bid for contraceptive

EPO reports record patent filings, but pharma and biotech lag

Part II: The race to replace semaglutide heats up

Masimo convinces judge that Apple took secrets—but it’s not enough

Sandoz strikes fresh biosimilar deal with South Korean biotech

HSF Kramer hires patent litigator as partner in Germany

INTA: ‘New normal’ for in-house counsel as budgets fall

EU Pharma Package hits the final stretch—but can negotiators agree?

More on this story

Editor's picks

Editor's picks

More features